Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» ALS
ALS
FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit
FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit
MedCity News
BrainStorm Cell Therapeutics
ALS
stem cell therapy
clinical trials
FDA
Flag link:
Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway
Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway
Endpoints
BrainStorm Cell Therapeutics
ALS
cell therapy
FDA
Flag link:
Stem cell therapy for ALS fails a large clinical trial
Stem cell therapy for ALS fails a large clinical trial
BioPharma Dive
ALS
clinical trials
stem cells
BrainStorm Therapeutics
Flag link:
Bristol Myers, insitro ally to apply machine learning to ALS R&D
Bristol Myers, insitro ally to apply machine learning to ALS R&D
Fierce Biotech
Bristol-Myers Squibb
Insitro
machine learning
ALS
artificial intelligence
Flag link:
Early signs of survival benefit raise optimism around a small biotech's ALS drug
Early signs of survival benefit raise optimism around a small biotech's ALS drug
BioPharma Dive
ALS
AMX0035
Amylyx Pharmaceuticals
Flag link:
Biogen teams up with gene-editing startup Scribe on ALS program
Biogen teams up with gene-editing startup Scribe on ALS program
Pharmaforum
Scribe Therapeutics
Biogen
ALS
CRISPR
Flag link:
Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines
Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines
Forbes
Jennifer Doudna
gene editing
Scribe Therapeutics
ALS
Flag link:
Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders
Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders
Xconomy
ALS
Libra Therapeutics
Flag link:
After a rare win, a biotech details long-awaited results for its ALS drug
After a rare win, a biotech details long-awaited results for its ALS drug
BioPharma Dive
ALS
AMX0035
Amylyx
FDA
Flag link:
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
BioSpace
Biogen
ALS
tofersen
BIIB067
clinical trials
Flag link:
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Fierce Biotech
Amylyx Pharmaceuticals
funding
ALS
Alzheimer's disease
Flag link:
Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases
Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases
BioSpace
Yumanity Therapeutics
Merck
ALS
frontotemporal lobar dementia
R&D
Flag link:
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
BioSpace
Denali Therapeutics
Sanofi
DNL747
ALS
Alzheimer's disease
DNL788
clinical trials
Flag link:
Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments
Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments
BioSpace
Amgen
QurAlis
ALS
Flag link:
I Have a Dream… Five Dreams for Biotech
I Have a Dream… Five Dreams for Biotech
BioSpace
biotech
patients
Alzheimer's disease
ALS
HIV
cancer
drug pricing
Flag link:
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Yahoo/Zacks.com
Alexion
ALS
Ultomiris
clinical trials
Flag link:
First-of-its-kind trial in ALS spurs hope for brutal disease
First-of-its-kind trial in ALS spurs hope for brutal disease
BioPharma Dive
ALS
clinical trials
Implicit Bioscience
Prilenia Therapeutics
Clene Nanomedicine
Ra Pharma
Biohaven
Flag link:
5 years later, Ice Bucket Challenge's impact on drug research still unfolding
5 years later, Ice Bucket Challenge's impact on drug research still unfolding
Bizjournals
ALS
fundraising
drug development
Flag link:
In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug
In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug
Endpoints
Biohaven
FDA
riluzole
Apotex
ALS
Flag link:
Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns
Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns
BioSpace
Mallinckrodt
ALS
clinical trials
pneumonia
H.P. Acthar Gel
Flag link:
Pages
1
2
3
4
next ›
last »